Every one of those 1 sits in a single category, pharma. Sinopharm is most often covered alongside OSR Company, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Sinopharm
Every one of those 1 sits in a single category, pharma. Sinopharm is most often covered alongside OSR Company, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.6 for the same window. The average consequence score is 6, matching the 6 beat baseline for this window. Sinopharm appears in 1 tracked Biotech story from March 19, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Sinopharm. Shared-story counts are live from our verified record — not editorial picks.
Woori IO, a subsidiary of OSR Company, has entered into a strategic Non-Disclosure Agreement (NDA) with Chinese pharmaceutical giant Sinopharm to explore commercialization opportunities in mainland China. The partnership also outlines a framework for collaboration on global multicenter clinical trials, signaling a major expansion for OSR's therapeutic pipeline into the world's second-largest pharmaceutical market.
